Hyperlipidemia drug market seen reaching $35.82 billion by 2035

Market Research Future projects the global hyperlipidemia drug market will grow from $26.19 billion in 2026 to $35.82 billion by 2035, driven by rising dyslipidemia rates, tighter LDL-C targets and broader use of biologics and siRNA therapies. The forecast points to faster growth in PCSK9 inhibitors, injectable treatments and online distribution as payers and health systems expand access.

Why it matters: - The market is shifting from low-cost generic statins toward higher-value biologics and siRNA therapies. - That shift could reshape how insurers, health systems and manufacturers manage long-term cardiovascular prevention. - The forecast assumes durable demand tied to rising dyslipidemia and stricter treatment goals, not short-term consumer spending.

What happened: - Market Research Future projected the global hyperlipidemia drug market will rise from $26.19 billion in 2026 to $35.82 billion by 2035. - The forecast implies a 3.54% compound annual growth rate from 2026 to 2035. - The market base was estimated at $25.38 billion in 2025. - The research release was issued July 7, 2026. - A free sample is available here.

The details: - More than 2.1 billion adults live with dyslipidemia, according to the release. - The World Heart Federation and WHO data cited in the release say raised total cholesterol affects about 39% of adults globally. - The WHO estimates cardiovascular conditions cause 17.9 million deaths worldwide each year. - Updated ACC/AHA and ESC/EAS guidance is lowering LDL-C treatment thresholds and widening use of nonstatin add-on therapies. - The release highlights a therapeutic shift from oral statins to PCSK9 inhibitors, inclisiran and next-generation small molecules. - NIH-cited clinical data in the release says small-interfering RNA therapies can cut LDL cholesterol by up to 50% on average. - The release says twice-yearly dosing helps address adherence problems seen with daily oral regimens. - Between 2022 and 2024, venture and pharma license deals targeting next-generation lipid modulators topped $4.7 billion, according to the release. - Statins remained the dominant drug class in 2025 with about 72.5% revenue share. - Atorvastatin accounted for about 35% of global lipid-lowering prescriptions, while rosuvastatin held about 22%, according to the release. - PCSK9 inhibitors were the fastest-growing drug class, with a projected 4.0% CAGR from 2026 to 2035. - Evolocumab and alirocumab generated combined global sales above $4.2 billion in 2024. - Bempedoic acid and ezetimibe are gaining use for patients who cannot tolerate statins. - Inclisiran is positioned as the first-in-class siRNA lipid-lowering therapy with twice-yearly dosing. - The NHS England rollout aims to reach 300,000 high-risk patients. - By indication, primary hyperlipidemia held about 48% of demand in 2025, equal to roughly $12.18 billion. - Secondary hyperlipidemia represented $4.87 billion in 2025. - By route, oral drugs led the market with 60.6% share in 2025. - Injectable therapies were the fastest-growing route, at a projected 4.8% CAGR. - By distribution, retail pharmacies held about 45.8% share in 2025. - Hospital pharmacies accounted for $7.24 billion in 2025. - Online pharmacies were the fastest-growing channel, at a projected 5.2% CAGR. - North America led the market with about 42.0% share in 2025. - The United States generated about 85.2% of North American revenue. - CMS’s 2025 Medicare Part D redesign capped annual out-of-pocket costs at $2,000, improving access for seniors. - Europe was the second-largest region with about 28.1% share in 2025. - Asia-Pacific was the fastest-growing region, with a projected 5.4% CAGR from 2026 to 2035. - China held 38.5% of Asia-Pacific revenue and negotiated PCSK9 inhibitor prices down by 60% to 80% in 2024. - India is projected to grow at 5.8% CAGR on expanded lipid screening under Ayushman Bharat. - The Middle East and Africa region is projected to grow at 2.7% CAGR from 2026 to 2035. - South America generated $1.78 billion in 2025, with Brazil accounting for about 62.4% of regional revenue. - The market is moderately concentrated, with an estimated Herfindahl-Hirschman Index of 1,200 to 1,500. - The top five companies control about 55% to 62% of global revenue. - Pfizer holds about 12% to 16% of global revenue. - Amgen holds about 8% to 12% of global revenue. - Sanofi and Regeneron hold about 7% to 11% of global revenue. - AstraZeneca holds about 6% to 9% of global revenue.

Between the lines: - The opportunity is being driven less by volume alone and more by access to premium therapies, outcomes data and payer coverage. - Tightening LDL-C targets create a larger pool of patients who qualify for add-on treatment. - Injectable and twice-yearly therapies matter because adherence remains a major barrier in chronic lipid management. - The market still depends on payer decisions, step therapy and formulary access, which can slow uptake even when clinical demand is strong. - Patent cliffs in branded statins and the coming biosimilar window for PCSK9 antibodies could increase competition and pressure pricing.

What's next: - Reimbursement will increasingly hinge on real-world outcomes and measured lipid reduction, especially by 2030. - Oral PCSK9 inhibitors and next-generation small molecules could broaden advanced lipid treatment into primary care in the early 2030s. - The NHS England rollout and similar public-health programs will be an early test of population-scale adoption. - More markets are likely to expand screening, which should convert undiagnosed dyslipidemia into prescription demand.

The bottom line: - Hyperlipidemia drugs are moving into a higher-value growth phase, led by biologics, siRNA and broader prevention coverage rather than legacy statin volume alone. - More information is available in the company's detailed report.